Using Upadacitinib for treating moderate-severe atopic dermatitis in adults
Esperienza Real-world Sull'Uso di Upadacitinib Nel Trattamento Della Dermatite Atopica Moderata-severa Dell'Adulto
This study is testing how well Upadacitinib works for adults with moderate to severe atopic dermatitis who haven't had success with other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse Academic / other |
| Drugs / interventions | upadacitinib |
| Locations | 1 site (Roma) |
| Trial ID | NCT05989932 on ClinicalTrials.gov |
What this trial studies
This study observes the real-world experience of using Upadacitinib, a new oral medication, for adults suffering from moderate to severe atopic dermatitis. It aims to assess the effectiveness and safety of this treatment in patients who have not responded to traditional therapies. The study will involve patients who have received approval for compassionate use of Upadacitinib, allowing for a better understanding of its impact in a clinical setting. The research will also consider various factors such as disease severity and patient needs in treatment decisions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with moderate to severe atopic dermatitis.
Not a fit: Patients who are unable to provide informed consent or complete the required study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients with moderate to severe atopic dermatitis who have not benefited from existing therapies.
How similar studies have performed: Other studies have shown promising results with similar JAK inhibitors in treating atopic dermatitis, indicating a potential for success with this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 years 2. Signature of informed consent 3. Diagnosis of moderate and/or severe DA by a dermatologist specialist 4. Approval of the compassionate use of upadacitinib Exclusion Criteria: 1. Patient unable to give informed consent prior to any collection procedure study data 2. unable to complete the procedures required for the study
Where this trial is running
Roma
- Irccs Fondazione Policlinico Gemelli — Roma, Italy (Recruiting)
Study contacts
- Study coordinator: Ketty MD Peris
- Email: ketty.peris@unicatt.it
- Phone: 0630154211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.